CD19 and B-cell acute lymphoblastic leukemia: Blinatumomab, a bispecific antibody targeting the B lymphocyte antigen CD19, and tisagenlecleucel, a chimeric antigen receptor (CAR)-T cell therapy targeting CD19, are approved for treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (93, 96, 97).